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Potential for Promoting Recurrent Laryngeal Nerve Regeneration
by Remote Delivery of Viral Gene Therapy
Adam D. Rubin, MD; Norman D. Hogikyan, MD; Alex Oh; Eva L. Feldman, MD, PhD
Objectives/Hypothesis: The aims of this study were to demonstrate the ability to enhance nerve regeneration by
remote delivery of a viral vector to the crushed recurrent laryngeal nerve (RLN), to demonstrate the usefulness of a crushed
RLN model to test the efficacy of viral gene therapy, and to discuss future potential applications of this approach.
Study Design: Animal study.
Methods: Adult Sprague-Dawley rats were assigned to two groups. In the experimental group, an adeno-associated viral
(AAV) vector carrying a zinc-finger transcription factor, which stimulates endogenous insulinlike growth factor I production
(AAV2-TO-6876vp16), was injected into the crushed RLN. In the control group, an AAV vector carrying the gene for green flu-
orescent protein was injected into the crushed RLN. Unilateral RLN paralysis was confirmed endoscopically. At 1 week, laryn-
geal endoscopies were repeated and recorded. Larynges were cryosectioned in 15-lm sections and processed for acetylcho-
line histochemistry (motor endplates) followed by neurofilament immunoperoxidase (nerve fibers). Percentage nerve-
endplate contact (PEC) was determined and compared. Vocal fold motion was evaluated by blinded reviewers using a visual
analogue scale (VAS).
Results: The difference between PEC on the crushed and uncrushed sides was statistically less in the experimental
group (0.54 6 0.18 vs. 0.30 6 0.26, P ¼ .0006). The VAS score at 1 week was significantly better in the experimental group
(P ¼ .002).
Conclusions: AAV2-TO-6876vp16 demonstrated a neurotrophic effect when injected into the crushed RLN. The RLN
offers a conduit for viral gene therapy to the brainstem that could be useful for the treatment of RLN injury or bulbar motor
neuron disease.
Key Words: Gene therapy, viral vectors, vocal fold paralysis, reinnervation, neurologic disease, amyotrophic lateral
sclerosis, adeno-associated virus, dysphonia.
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INTRODUCTION
Peripheral nerve injury and other neurologic proc-
esses affecting motor neurons, such as spinal cord injury
and motor neuron disease, can be devastating and often
fatal disorders. Our ability to treat these disorders is
suboptimal, and improving therapy remains one of the
biggest challenges facing medicine today.
Preservation of injured motor neurons is necessary
to restore functional innervation of muscles. Depending
on the nature of injury to a peripheral nerve, neuronal
degeneration may occur in different ways. Degeneration
of the distal axon (Wallerian degeneration) occurs with
axotomy. In neurodegenerative processes, ‘‘dying back’’
degeneration toward the cell body occurs. The cell body
lasts for a longer period of time but also can die. The
cell body is critical for supplying much of the metabolic
milieu for axonal regeneration.1 If the cell body dies,
axonal regeneration will not occur. Therefore, efforts
must be made to preserve the cell soma.
An appealing strategy to protect neurons is to
deliver neurotrophic growth factors to the motor neuron
cell body located in the central nervous system (CNS).2–5
However, this can be challenging. These peptides do not
cross the blood brain barrier and often result in deleteri-
ous side effects when delivered into the bloodstream.
Delivery directly to the cerebrospinal fluid or CNS
parenchyma carries risk of further injury. Furthermore,
the growth factors have poor diffusion capability, which
limits the effectiveness of intraparenchymal injections.2,3
The delivery of exogenous genes encoding therapeu-
tic growth factors or activators of endogenous growth
factor production is an exciting alternative to delivering
the growth factors themselves. Ideally, transgene-carry-
ing vectors could provide sustained transcription of a
therapeutic gene to the specific neurons of interest.
Transgene expression in vivo may be accomplished in
several ways. Cell lines may be designed in vitro to con-
stitutively express therapeutic transgenes. These cell
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lines would then be delivered directly into the paren-
chyma of interest6; however, the inherent risk of inducing
further trauma to the compromised area must be taken
into account with this approach. Alternatively, neurotro-
phic viral vectors carrying the desired transgenes can be
constructed. Such viral vectors can be injected into the
peripheral nervous system or adjacent tissue for selective
transport into the CNS via retrograde axonal trans-
port.2,3,7–11 This technique avoids the potential trauma of
direct injection by instead delivering the vector remotely
to more surgically accessible nerves or muscles. It also
adds the potential advantage of cell selectivity, as one can
target specific motor neurons by injecting into the appro-
priate target muscle or peripheral nerve.
Herpes simplex virus, retroviruses, adenovirus, and
adeno-associated virus (AAV)2–4,7–10,12 have all been
applied in vivo for gene transfer to the nervous system.
Viruses are attenuated using standard techniques for
gene insertion and deletion. Local proliferation is pre-
vented by removing necessary parts of the viral genome,
and potentially therapeutic genes are inserted. Adenovi-
ruses have been the predominant vectors used for gene
therapy to the nervous system, but they do have recog-
nized disadvantages. The primary disadvantage is limited
duration of gene expression. Other vector delivery sys-
tems have been developed to prolong gene expression
including ‘‘gutted’’ adenovirus (from which potentially im-
munogenic genes are deleted), lentiviruses, and AAV.2,3
The purpose of this study was severalfold: first, to
demonstrate the ability to enhance nerve regeneration
by remote delivery of a viral vector to the crushed recur-
rent laryngeal nerve (RLN); second, to demonstrate the
usefulness of a crushed RLN model to test the efficacy of
viral gene therapy; and third, to discuss future potential
applications of this approach.
MATERIALS AND METHODS
Rat Surgeries
Ten adult Sprague-Dawley rats were assigned randomly to
two groups of five. Rats were anesthetized with intraperitoneal
ketamine (77 mg/mL) and xylazine (4.62 mg/mL) for induction.
Preoperative vocal fold mobility was confirmed by laryngeal en-
doscopy. Anesthesia was maintained with isoflurane (0.8% to
1.5%) delivered by a nose cone. A vertical cervical incision was
made, followed by division of the platysma and strap muscula-
ture. Using a dissecting microscope (Stereozoom 6; Leica,
Buffalo, NY), the right RLN was exposed and dissected circum-
ferentially from the midtrachea to the inferior margin of the
right thyroid lobe. The nerve was then crushed with a jeweler’s
forceps at the level of the sixth tracheal ring for 30 seconds.
Each nerve was crushed by the same investigator. The investi-
gator was not aware of which viral vector the rat would receive.
Viral injection was then performed (described later), and the
wound was closed in a multilayer fashion. All experiments con-
ducted in the present study were reviewed and approved by the
University of Michigan Committee on Use and Care of Animals
and the University of Michigan Biological Research Review
Committee before initiation.
Laryngeal Endoscopy
Laryngeal endoscopy was performed after each crush pro-
cedure to confirm unilateral vocal fold paralysis. Endoscopic
examinations were recorded onto a digital recording device
(Stryker endoscopic tower, 30-degree endoscope; Stryker Endo-
scopy, San Jose, CA). Vocal fold motion was recorded while
the rats breathed spontaneously. Endoscopy was also performed
after induction anesthesia before sacrifice at 1 week.
Viral Injections
The right RLN of rats in the experimental group was
injected with 5 lL of AAV2-TO-6876vp16 (insulinlike growth
factor [IGF] activator) 6.55e8 vg/mL (Lot # 05-120B; Applied
Viromics, Freemont, CA) (Sangamo Biosciences; Richmond, CA)
using 70 nL boluses (5% volume error). This is an AAV vector
carrying the transgene for an IGF-I transcription factor. The
advantage of employing the engineered zinc finger transcription
protein for production of IGF-I is that it allows for the endoge-
nous production of all IGF-I isoforms, not just specific isoforms,
as would occur with the other more standard approaches. A
concentration of 6.55  108vg/mL was used. The right RLN of
rats in the control group was injected with AAV2CMVeGFP.
This is an AAV vector carrying the transgene for green fluores-
cent protein (GFP). A concentration of 4.41  1012 vg/mL was
used.
A glass micropipette puller (PP-83; Narishige, Tokyo,
Japan) was used to taper micropipette tips to a 50-lm size.
Micropipettes were advanced beneath the perineurium along
the nerve using an oocyte microinjector and micromanipulator
(Nanoject; Drummond, Broomall, PA). Gentle counter traction
was placed on the nerve during viral injection, using a 5-0 poly-
propylene suture.
Sacrifice
Prior to euthanasia at 1 week, rats were anesthetized and
endoscopy was performed. Endoscopic data were recorded on a
digital recorder. Intracardiac perfusion (98.75 mL of 1 phos-
phate buffer [PB] solution and 1,250 units of heparin) was
performed. The larynx was removed and placed into 2-methyl
butane surrounded by a bath of liquid nitrogen for 5 seconds
and was then wrapped in aluminum foil and placed into the




Cryosections (20 lm) were processed for acetylcholine
histochemistry (motor endplates) followed by neurofilament
immunohistochemistry (nerve fibers). The sections were
hydrated in water and placed in sodium sulfate (20% solution
in water) for 5 minutes. The sections were rinsed in water
followed by incubation in acetylcholinesterase solution (5-bro-
moindoxyl acetate, 4.0 mg; ethanol, 0.3 mL; potassium
ferrocyanide, 63.0 mg; potassium ferricyanide, 50.0 mg; Tris
hydrochloric acid, 42.0 mg; Tris base, 4.0 mg; calcium chloride,
33.0 mg; and deionized water, 30.0 mL) and incubated for up to
1.5 hours at 37C until bright blue endplates could be clearly
distinguished.
Following the acetylcholinesterase staining, the sections
were rinsed in PB (11.9 mM phosphates, 137 mM sodium chlo-
ride, and 2.7 mM potassium chloride). The sections were placed
in hydrogen peroxide (0.5% in PB) for 10 minutes to quench
endogenous peroxidase activity followed by two 10-minute
rinses in PB. The sections were blocked in PB containing 0.1%
Triton-X (Sigma, St. Louis, MO) 100, 2% nonfat dry milk, and
1% normal serum to reduce nonspecific adherence of antibody.
Primary antibody (polyclonal, neurofilament, 1:1,000, Cat#
AB1981; Chemicon International Inc., Temecula, CA) was
applied, and the sections were incubated over night at
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room temperature. Following primary antibody, sections were
incubated with secondary antibody (anti-rabbit IgG biotinyl-
ated, Vectastain ABC kit, Cat# PK4001; Vector Laboratories,
Inc., Burlingame, CA) and developed with Vectastain ABC and
DAB (Peroxidase substrate kit; Vector Laboratories, Inc.). The
sections were rinsed with PB and dehydrated through ethanol
(50% for 2 minutes, 70% for 2 minutes, 95% for 2 minutes
[twice], 100% for 2 minutes [twice], and xylene for 10 minutes
[twice]) and mounted with DPX (Electron Microscopy Sciences,
Hatfield, PA).
Data Analysis
Percentage nerve-endplate contact. Percentage nerve-
endplate contact (PEC) was determined by manually counting
the total number of endplates making contact with neurofila-
ment and dividing by the total number of endplates present in
each section under light microscopy (40). This was performed
by a single blinded investigator not involved in the histologic
preparation of the slides. Approximately every seventh section
was evaluated. PEC was recorded as a fraction of 1 (for exam-
ple, 80% is recorded as 0.80).
Endoscopy data. Endoscopic examinations were random-
ized and placed on CD-ROMs, which were sent to two
fellowship-trained laryngologists unaware of the purpose of the
experiment. The reviewers were provided a visual analogue
scale (VAS) (Fig. 1) and asked to evaluate right-sided vocal fold
motion in relation to the left vocal fold. The reviewers scored
examinations from day 0 of the control group and from day 7 of
the control and experimental groups. The reviewers’ scores
were quantified by measuring the distance between the scores
and the ‘‘normal’’ end of the VAS. Of note, the digital recorder
failed to record the endoscopic examinations from day 0 in the
experimental group; therefore, these data were not evaluated
by the blinded reviewers. However, vocal fold paralysis had
been confirmed in all the members of this group after nerve
crush. Furthermore, the day 0 data were not important in the
statistical analysis.
Statistical analysis. Data were entered into an excel
spreadsheet and cleaned. Standard t tests were used to compare
groups. P < .05 was considered statistically significant.
RESULTS
PEC was measured for the crushed (right) and
uncrushed (left) side in each group. The left side was
used as an internal control for each group. The differ-
ence between PEC on the crushed and uncrushed sides
was statistically less in the experimental group (0.54 6
0.18 vs. 0.30 6 0.26, P ¼ .0006), suggesting faster
reinnervation or less denervation in the group treated
with the viral vector carrying the IGF-I activator gene
(Table I).
At day 0 (immediately after crush), the mean VAS
score for right vocal fold movement was 99 6 1.5 mm.
At day 7, the mean VAS scores were 40 6 33.2 mm in
the control group and 5.6 6 6.7 mm in the experimental
group. A lower VAS score reflects greater vocal fold
mobility. A score of 0 suggests normal mobility, and a
score of 100 mm indicates no movement (paralysis). The
difference in VAS scores at day 7 between the experi-
mental and control group is statistically significant (P ¼
.002) (Table II).
DISCUSSION
Nerve cells, unlike other cells in the body, do not
divide or replicate; once neurons are lost, the body
cannot replace them. Therefore, preventing neuronal
loss is critical after nerve injury or disease to have the
best chance of functional recovery. To date, most of the
research in neuronal protection has been focused on
preservation or protection of cell bodies within the spinal
cord. Approaches fall into four main categories: deliver-
ing neurotrophic factors, delivering stem cells, blocking
endogenous growth-inhibiting signals, and inhibiting the
inflammatory response after injury.13 In clinical practice,
the only accepted approach to date for preventing per-
manent nerve injury is providing high-dose steroids. If
high-dose methylprednisolone is given within 8 hours of
spinal cord injury, patients are more likely to have
improved motor and sensory outcomes.14 Steroids also
are used for cranial nerve injuries. They are recom-
mended for the treatment of acute facial nerve
paralysis15 and frequently are used in the treatment of
sudden sensorineural hearing loss.16 Treatment of motor
nerve injury remains suboptimal, however, and efforts
must continue to find better methods of neuronal preser-
vation and repair.17,18
Efforts to develop more effective approaches to pro-
moting neuronal survival and function following injury
have focused on neurotrophic factors. Most of these neu-
rotrophic factors are produced by glial cells within the
central and peripheral nervous system, including IGF-
I,4,5,19–22 brain-derived neurotrophic factor,23 neurotro-
phin-3,24 nerve growth factor,25 and glial cell–derived
Fig. 1. Visual analogue scale used for blinded evaluation of
recorded rat endoscopies. Scores were measured as distance
from normal movement end.
TABLE I.
Difference Between Percentage Nerve Endplate Contact in Crushed Versus Uncrushed Sides in Rats Injected






Left and Right Sides
Experimental group (injected with activator gene vector) 0.84 6 0.10 0.54 6 0.23 0.30 6 0.26
Control group (injected with empty vector) 0.74 6 0.10 0.20 6 0.16 0.54 6 0.18
The difference is smaller in the group injected with the activator gene, demonstrating enhanced regeneration or less degeneration (P < .0006, t test).
PEC ¼ percentage nerve-endplate contact.
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neurotrophic factor.26 Although vascular endothelial-
derived growth factor was discovered as a factor that
stimulates endothelial cell division and migration, lead-
ing to new blood vessel formation, both in vivo and in
vitro studies have demonstrated it also has neurotrophic
properties.27,28
IGF-I has a number of characteristics that make it
a particularly attractive therapeutic candidate. Not only
does it enhance neuronal survival, it stimulates neurite
outgrowth, myelination, and neuronal migration. It acts
in both the central and peripheral nervous systems and
is the only growth factor involved in both sensory and
motor nerve regeneration.4,5,21,22 Potentially, it should
be useful in the treatment of a number of pathologic
processes, including peripheral nerve injury, spinal cord
injuries, demyelinating disease, and degenerative neuro-
muscular diseases.
Multiple models of peripheral nerve injury have
demonstrated improved regeneration after treatment
with IGF-I.21,22,29,30 Rat models have demonstrated that
endogenous IGF-I and IGF-I receptor are upregulated
after sciatic nerve injury, suggesting an endogenous
response to an attempt to stimulate neurite out-
growth.21,31,32 In diabetic rat models, however, this
upregulation is impaired. Furthermore, reduced serum
levels of IGF-I and IGF-I receptor have been demon-
strated in human patients with diabetic neuropathy,
suggesting this may play a role in the pathophysiology
of the disease.21,33 Shiotani et al.34 demonstrated that
IGF-I had neurotrophic effects when delivered to the rat
thyroarytenoid muscle after RLN transection. Rats that
received a nonviral muscle-specific vector carrying the
gene for IGF-I demonstrated increased muscle fiber
diameter, shorter motor endplate length, and an
increased PEC 28 days after RLN transection.3,34
Viral vectors remain an attractive approach for
therapeutic transgene delivery to injured motor neurons.
AAV vectors have become frequently used vehicles for
gene therapy. Advantages to AAV compared to tradi-
tional adenoviral vectors include the following: duration
of transcription, with some studies reporting persistence
for years; lack of pathogenicity of the wild-type virus;
less immunogenicity; and numerous available serotypes.
Although wild-type AAV has been reported to integrate
into chromosome 19q13.4, establishing latency, currently
available AAV vectors are not able to integrate into host
DNA.35
Rather than express a therapeutic growth factor,
the vector used in this study carried a gene for a zinc
finger protein (ZFP) transcription factor (TF). ZFP-TFs
are activator genes that stimulate endogenous produc-
tion of growth factors. ZFPs recognize and bind to
specific DNA sequences. They are the largest class of
DNA-binding domains found in human transcription fac-
tors36 and can be paired with either activator or
repression domains. For example, the VP16 domain from
herpes simplex virus and p65 domain from the NF-jB
transcription factor are used to create activator TFs.
These TFs can bind a DNA sequence within a promotor
to drive endogenous expression of a gene or in vitro
expression of a transgene.36 ZFP-TFs have been shown
to increase protein production in mammalian cells.37
Snowden et al. used ZFP-TF to repress vascular endo-
thelial growth factor–A in human cancer cell lines. ZFP-
TFs have been designed to increase endogenous produc-
tion of the human erythropoietin gene39 and vascular
endothelial growth factor.40 An advantage of using ZFP-
TFs as opposed to exogenous therapeutic transgenes is
the endogenous production of all splice variants of a
growth factor in the correct proportions. Appropriately
proportioned expression of all splice variants is impor-
tant for cellular regulation.41,42
Peripheral injection of viral vectors into surgically
accessible nerve or muscle is the least invasive way to
deliver viral vectors to the CNS. It also offers motor neu-
ron selectivity by delivering to specific motor neurons.
The sciatic nerve has been used to deliver vectors to the
spinal cord.11,43 A crushed sciatic nerve model has been
used extensively to investigate remote delivery of viral
vectors to the spinal cord. Studies have demonstrated
that peripheral injection into nerve results in greater
CNS gene expression than delivery into muscle.11 Intra-
neural colchicine inhibits delivery of peripherally
injected vectors to the CNS, suggesting that the vectors
are delivered by retrograde axonal transport.44 Further-
more, modifications of viral vectors using small peptides
such as Tet-1 may enhance retrograde axonal transport,
resulting in quicker, more efficient delivery to the CNS,
and enhance cell selectivity.44
To target the brainstem, cranial nerves must be
used. We have demonstrated that both adenoviral and
AAV vectors can be delivered to the rat brainstem via
peripheral injection into the crushed rat RLN.2,3 Using
an AAV vector carrying the gene for GFP, we reported
expression for as long as 3 weeks. Similar to findings in
sciatic nerve experiments, expression of the transgene is
seen extensively in the target nucleus (nucleus ambi-
guus) but also beyond the nucleus and on the
contralateral side, suggesting transsynaptic delivery of
the virus within the CNS.2,3,11,43 Via fluorescent in situ
hybridization we demonstrated that the virus itself, and
not just the expressed transgene product, is delivered to
the neurons in the nucleus ambiguus.2,3
The crush model of RLN injury used in the current
study was developed to test the efficacy of viral vectors
delivered to the brainstem to enhance neuronal regener-
ation. Similar to work by Shiotani et al.34 to assess
injury after RLN transection in the rat, PEC is
TABLE II.








98.5 6 1.6 5.3 6 6.7 39.8 6 33.2
Millimeters from normal motion as recorded on a visual analogue
scale by two blinded reviewers when asked to evaluate endoscopic record-
ings of rat vocal fold motion within each group at day 7 and day 0. A larger
number signifies less vocal fold motion (maximum, 100 mm). The closer the
number is to 0, the greater the vocal fold motion. Rats that received the
insulinlike growth factor–I activator gene had significantly greater gross
vocal fold motion at day 7 (P < .002, t test).
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evaluated. Modifications were made to streamline the
tissue processing. The immunohistochemical technique
used in this study was developed to replace the silver
impregnation technique of Pestronk and Drachman.45
Silver easily precipitates and often involves tedious care
of all glassware. The techniques used in the current
study to stain neurofilaments and motor endplates are
just as effective for tissue evaluation and easier to per-
form (Fig. 2).
The natural time course of injury to regeneration
after crush injury to the RLN suggests a window of op-
portunity for detecting a positive effect of viral gene
therapy. Crush yields a Sunderland type 2 injury, and
normally full recovery is expected after a few weeks. At
1 week after RLN crush, PEC drops to 20%. By 2 weeks
after crush, PEC increases to 54%, and full recovery
(80% PEC) is seen at 3 weeks. These data suggest that
the optimal time to observe an effect of a viral vector
would be at the 1 week time point.46 AAV2-TO-6876vp16
used in the current experiment accelerated regeneration
or limited degeneration so that more than 50% PEC was
observed at 1 week (Table I) (Fig. 2). Furthermore, the
blinded endoscopic evaluations strongly demonstrated
earlier functional return in the rat groups treated with
remote injection of the viral vector (Table II).
We have also demonstrated in previous work that
injection of virus into the RLN creates no significant
additional injury when performed after crush.2 Neuronal
death may occur after adenovirus is directly injected
into CNS parenchyma. Injury may be due to mechanical
insult from the injection, host immune response, neuro-
nal transduction by a large number of viral particles, or
toxicity of the viral capsid. All of the above mechanisms
require exposure of the cell body or surrounding antigen
presenting cells to viral capsids. Direct exposure to cap-
sids is reduced by injecting peripherally.2,3,43,11
The purpose of a nerve crush model is not to inves-
tigate how to enhance regeneration after a crush injury
in clinical practice. Crush injuries typically recover fully
without any intervention. Rather, the purpose is to pro-
vide an instrument to test the efficacy of potentially
useful viral vectors. The crush model offers several
advantages, including being able to observe an effect in
a short period of time. This can reduce significant study
expenses, such as animal housing and care.
In terms of RLN injuries in clinical practice, per-
haps the most pressing issue is how to restore vocal fold
motion after RLN transection. Although a neurorrhaphy
can be performed, this seldom results in restored vocal
fold function. Even if neuronal regeneration could be
enhanced after neurorrhaphy, this would likely not
restore vocal fold motion due to synkinesis—nonspecific
reinnervation of abductor and adductor muscles. Cur-
rent treatment techniques for unilateral vocal fold
paralysis, including injection laryngoplasty, type-I thyro-
plasty, arytenoid adduction, and reinnervation, provide
only a geometric solution by medializing or preventing
atrophy of the paralyzed vocal fold to improve glottic
closure.
Reinnervation procedures have been described to
try to avoid synkinesis, primarily by trying to promote
regeneration from nerves that fire in a coordinated fash-
ion during adduction or abduction. Muscle-nerve-muscle
neurotization is a promising technique in which a graft
Fig. 2. Nerve endplate contact (20). (A) Thyroarytenoid muscle
on uncrushed side after acetylcholinesterase and neurofilament
immunohistochemistry. Blue are endplates, brown is neurofila-
ment. High percentage of endplates are touched by neurofilament.
(B) Thyroarytenoid muscle 1 week after recurrent laryngeal nerve
(RLN) crush in a group treated with AAV2-TO-6876vp16 (insulinlike
growth factor–I activator gene). Approximately half of motor end-
plates are contacted by neurofilament. (C) Thyroarytenoid muscle
1 week after RLN crush in group treated with AAV2CMVeGFP (no
activator gene). Fewer than half of the motor endplates are con-
tacted by neurofilament.
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is interposed between the paralyzed intrinsic laryngeal
muscle and a contralateral muscle with the same func-
tion (e.g., adductor to adductor).47 The delivery of
retrograde viral vectors to the donor neurons could
enhance the effectiveness of regeneration and thus the
success of such procedures. Restoring motion to a para-
lyzed vocal fold would be the ideal treatment.
Ultimately, ensuring neuronal survival and enhancing
nerve regeneration will be necessary to achieve this
goal. Gene therapy can be useful in this pursuit.
Using the RLN to deliver factors back to the brain-
stem may also be useful in the treatment of bulbar
involvement of neurodegenerative disorders, such as
amyotrophic lateral sclerosis (ALS).4–6 Although retro-
grade transport might be compromised in ALS,
successful retrograde delivery in the SOD1 mouse model
of ALS has been reported.20,48 The ability to target spe-
cific nuclei, as well as the capability of viral vectors to
move transsynaptically to other neighboring nuclei
within the brainstem, offers some exciting possibilities
for the use of this technique in treating bulbar ALS and
other neurodegenerative diseases. Ideally, interventions
can be screened initially using the crush model in nor-
mal rats, as rat models of ALS are more costly to
produce and maintain.
Of course, the safety of viral gene therapy has been
in question, particularly since the tragic death of an 18-
year-old boy with an inherited liver disease who was
part of an adenoviral gene therapy protocol. The cause
of death was an overwhelming immune response to the
virus.49 Efforts to reduce the immunogenicity of viral
vectors continue. Phase I and II clinical trials are cur-
rently going on using AAV-2 vectors to treat diseases
including cystic fibrosis, Parkinson’s disease, rheumatoid
arthritis, and hemophilia, among others. Some immuno-
genicity and toxicity have been reported.35
Other approaches to motor neuron injury or degen-
eration also are being explored. Embryonic stem cell
research continues to hold great promise, and research
efforts will likely increase so long as they are not inhib-
ited by legal or political constraints. The potential of
stem cell treatment is mired, however, by the need to
control patterns of differentiation, the need for immuno-
suppression, and the ongoing moral debates that will
likely continue. Moreover, the two approaches may not
be mutually exclusive. Delivery of viral vectors may be
useful to promote stem cell survival and differentiation.
Viral gene therapy and stem cell therapy have the
potential to work together to treat complex human
diseases.48
CONCLUSION
This study and the body of investigative work that
led up to it demonstrate the potential of remote delivery
of therapeutic viral vectors to the injured RLN. Rats in
which AAV2-TO-6876vp16 (which carries a zinc-finger
transcription factor to enhance endogenous IGF-I pro-
duction) was injected remotely into the crushed RLN
demonstrated greater PEC and vocal fold mobility at 1
week than rats who did not receive the therapeutic
vector. The RLN offers a conduit for viral gene therapy
to the brainstem, a finding that could be useful for the
treatment of RLN injury or bulbar motor neuron dis-
ease. The crush model of RLN injury offers a practical
approach to screen the potential therapeutic value of
viral vectors.
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